Unlocking the power of the human genome
Microbiotica is a global leader in gut bacterial microbiology, genomics and identification of bacteria associated with health, disease or therapy from analysis of large clinical datasets. A pioneer in the use of the microbiome for therapeutics, the science underpinning the company stems from the cutting edge research happening at the Wellcome Sanger Institute.
Join us in this long read to discover how Microbiotica came to be, the science behind and the technology translation that made it possible.
Novel antibody therapeutics at Sanger’s first ever spin-out
The Wellcome Sanger Institute‘s first-ever spin-out, Kymab Ltd was acquired by Sanofi in 2021. Founded by the former Institute director and Sanger researcher, Allan Bradley, Kymab’s therapeutics are designed to modulate the immune system to overcome cancer immune tolerance and to treat autoimmune diseases. A great example of the power of innovation and technology translation.
Want to know how this incredible science became a tool to fight diseases?
Advancing healthcare through Genomics
Based on pioneering research from the Wellcome Sanger Institute and the UK NHS, Congenica, has a global footprint supporting leading international laboratories, academic medical centres, and biopharmaceutical companies and is the exclusive Clinical Decision Support partner for the NHS Genomic Medicine Service.
In this case study, we share the story of this spinout from the Wellcome Sanger Institute, how it is advancing healthcare through genomics and the role of the Technology Translation Team, which made this possible.
Three ambitious projects to fight malaria
Despite much progress that has been made to battle the disease, it remains a significant global healthcare challenge. It is found in more than 100 countries mainly in tropical regions of the world affecting millions of people; in 2018 an estimated 24 million children under 5 years of age were infected with P.falciparum in sub-Saharan Africa. Sanger’s researchers work towards the application of Sanger’s science in a number of areas such as drug discovery, vaccine discovery, epidemiological surveillance, diagnostics and precision medicine. This case study describes three ambitious Sanger projects focused on battling malaria.
Commercialising a database
In 2013, the advancing genomic revolution was increasing the rate of cancer mutational data available. At the same time, the cancer research community needed an accurate centralised database to aggregate and interrogate relevant data. How could we organise and curate exponentially growing amounts of data and protect this valuable resource of precious data for both academia and industry?
Working closely with COSMIC, Sanger’s Enterprise & Innovation Team devised and implemented a workable solution to help commercialise the COSMIC database.
This case study describes how it was done.
We’ve supported the creation of four spin-out companies to date; to learn more about Congenica, Kymab, Microbiotica and VHSquared
Find out more
Licensing is one way we disseminate knowledge and resources to benefit the scientific community and improve healthcare
Find out more